Table 1 Baseline demographic and clinical characteristics
Characteristics | Value |
|---|---|
Number of patients | 102 |
Observation period, days, median [range] | 733 [153–3278] |
Age, years, median [range] | 69 [34–89] |
Sex (men), n (%) | 70 (68.6) |
BMI in men, kg/m2, median [range] | 23.5 [16.2–33.8] |
BMI in women, kg/m2, median [range] | 23.0 [16.0–37.5] |
Baseline L3 SMI in men, cm2/m2, median [range] | 47.1 [31.5–64.4] |
Baseline L3 SMI in women, cm2/m2, median [range] | 36.5 [25.6–55.6] |
Etiology, n (%) | |
 HBV | 11 (10.8) |
 HCV | 50 (49.0) |
 NBNC | 41 (40.2) |
  Alcohol | 26 (25.5) |
  NASH | 7 (6.9) |
  PBC | 2 (2.0) |
  Cryptogenic | 6 (5.9) |
ALT, U/L, median [range] | 37 [9–243] |
Total bilirubin, mg/dL, median [range] | 1.0 [0.4–3.5] |
Albumin, g/dL, median [range] | 3.7 [2.0–4.9] |
Platelet count, × 104/μL, median [range] | 12.1 [2.2–80.9] |
Child-Pugh classification (A/B/C), n (%) | 68(66.7)/34(33.3)/0(0) |
AFP, ng/mL, median [range] | 21.8 [1.0–633,900] |
TNM stage (I/II/III/IV), n (%) | 11(10.8)/22(21.6)/46(45.1)/23(22.5) |
Maximum tumor diameter, mm, median [range] | 32 [9–198] |
Number of tumors (solitary/multiple), n (%) | 29(28.4)/73(71.6) |
Treatment sessions between CT exams, sessions, median [range] | 1 (1–6) |
Treatment modality (TACE/TAI/TACE+TAI), n (%) | 18(17.6)/25(24.5)/59(57.8) |
mRECIST assessment (CR/PR/SD/PD), n (%) | 18(17.6)/26(25.5)/9(8.8)/49(48.0) |
BCAA supplementation (presence/absence), n (%) | 72(70.6)/30(29.4) |
Cause of death (liver-related/infection/GI bleeding/others/unknown), n | 57/7/2/4/2 |